Stéphane Bancel, AP Images

Fi­nal analy­sis of US-fund­ed Mod­er­na Covid vac­cine tri­al shows 98% ef­fi­ca­cy against se­vere dis­ease

A fi­nal look at the re­sults of the place­bo-con­trolled Mod­er­na tri­al in the New Eng­land Jour­nal of Med­i­cine, pub­lished Thurs­day af­ter­noon, shows how the vac­cine con­tin­ues to pre­vent Covid-19 and se­vere cas­es af­ter more than five months fol­low­ing the sec­ond shot.

Of the more than 30,000 en­rolled in the tri­al that ul­ti­mate­ly led to the vac­cine’s EUA, on­ly two peo­ple in the vac­cine group got a se­vere form of the dis­ease, com­pared to 106 in the place­bo group — lead­ing to an ef­fi­ca­cy of 98%.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA